Logo image
Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer
Journal article   Open access   Peer reviewed

Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer

Mengshi Li, Xiuli Zhang, Thomas P Quinn, Dongyoul Lee, Dijie Liu, Falk Kunkel, Brian E Zimmerman, Daniel McAlister, Keith Olewein, Yusuf Menda, …
Applied radiation and isotopes, Vol.127(C), pp.52-60
09/2017
DOI: 10.1016/j.apradiso.2017.05.006
PMCID: PMC6295910
PMID: 28521118
url
https://www.osti.gov/biblio/1491308View
Open Access

Abstract

A method for preparation of Pb-212 and Pb-203 labeled chelator-modified peptide-based radiopharmaceuticals for cancer imaging and radionuclide therapy has been developed and adapted for automated clinical production. Pre-concentration and isolation of radioactive Pb2+ from interfering metals in dilute hydrochloric acid was optimized using a commercially-available Pb-specific chromatography resin packed in disposable plastic columns. The pre-concentrated radioactive Pb2+ is eluted in NaOAc buffer directly to the reaction vessel containing chelator-modified peptides. Radiolabeling was found to proceed efficiently at 85°C (45min; pH 5.5). The specific activity of radiolabeled conjugates was optimized by separation of radiolabeled conjugates from unlabeled peptide via HPLC. Preservation of bioactivity was confirmed by in vivo biodistribution of Pb-203 and Pb-212 labeled peptides in melanoma-tumor-bearing mice. The approach has been found to be robustly adaptable to automation and a cassette-based fluid-handling system (Modular Lab Pharm Tracer) has been customized for clinical radiopharmaceutical production. Our findings demonstrate that the Pb-203/Pb-212 combination is a promising elementally-matched radionuclide pair for image-guided radionuclide therapy for melanoma, neuroendocrine tumors, and potentially other cancers. •Pre-concentration of Pb-203 and Pb-212 via extraction chromatography resin was optimized for automated radiopharmaceutical production.•An HPLC isolation of Pb-203 and Pb-212 labeled peptides from unlabeled precursors produced specific activities near theoretical maximums.•The approach is robustly adaptable to automation and a cassette-based system was customized for clinical radiopharmaceutical production.
Peptides Alpha particle therapy Radionuclides Radiopharmaceuticals Pb-212 Pb-203

Details

Metrics

Logo image